Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-centre, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Phase 4 Efficacy and Safety Study of P-CAB (Tegoprazan 50 mg Once Daily) Compared With PPI (Rabeprazole 20 mg Once Daily) to Reduce Upper Gastrointestinal Events Including Bleeding and Symptomatic Ulcer Disease

NCT04416581 is registered in ClinicalTrials.gov with Duk-Woo Park, MD as lead sponsor.

NCT NCT04416581
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04416581 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-centre, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Phase 4 Efficacy and Safety Study of P-CAB (Tegoprazan 50 mg Once Daily) Compared With PPI (Rabeprazole 20 mg Once Daily) to Reduce Upper Gastrointestinal Events Including Bleeding and Symptomatic Ulcer Disease
Lead sponsor
Duk-Woo Park, MD
Phase
Phase 4
Overall status
Recruiting
Start date
May 12, 2021
Completion date
February 28, 2028
Enrollment
3,320 (estimated)
Sites
45

Conditions

As the registry lists them; a condition with its own page is linked.

acute coronary syndrome, coronary artery disease, myocardial infarction, percutaneous coronary intervention